OrganiGram Holdings Inc.

OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OrganiGram Holdings, Inc. engages in the provision of high-quality, indoor-grown cannabis for patients and adult recreational consumers and developing international business partnerships to extend the company’s global footprint. Its brands include Edison, Big Bag O’ Buds, SHRED, Monjour, and Trailblazer. The company was founded on July 5, 2010 and is headquartered in Toronto, Canada.

British American Tobacco

OrganiGram Holdings Inc's (NASDAQ: OGI) stock is likely to re-rate following the investment by a subsidiary of British American Tobacco PLC (NYSE: BTI), according to Cantor Fitzgerald. The OrganiGram Analyst: Pablo Zuanic maintained an Overweight rating for OrganiGram Holdings, while raising the price target from C$3.50 to C$6.

Why the British American Tobacco Investment In OrganiGram Is Important

Raymond James raised its stock price target on Canadian cannabis company Organigram Inc. to C$6 ($4.78) from C$3 on Friday, after the company announced a $176.6 million investment from British American Tobacco PLC and plan to cooperate in developing CBD products. "With its shiny new partnership with BAT, the wind is now at OGI's back, in our view," analysts Rahul Sarugaser and Michael W.

Organigram price target doubled by Raymond James on 'shiny new partnership' with British American Tobacco

Aurora Cannabis

Aphria

HEXO Corp

Altria

A major buy-in from a tobacco company lifts virtually the entire sector.

Why These Marijuana Stocks Blasted Higher Today

Did You Sell Your Organigram Holdings, Inc. Shares on Wednesday, March 10th? Are You Upset That the Stock Went Up Over 33 Percent Right After You Sold? Did You Sell Your Organigram Holdings, Inc. Shares on Wednesday, March 10th? Are You Upset That the Stock Went Up Over 33 Percent Right After You Sold?

Wolf Haldenstein Adler Freeman & Herz LLP Is Investigating Organigram Holdings, Inc.

Organigram Holdings Inc.'s U.S.-listed shares soared 30% Thursday, after the Canadian cannabis company said it has received a C$221 million ($176.6 million) investment from a unit of British American Tobacco PLC.

Cannabis Watch: Organigram shares rocket 30% as British American Tobacco buys 19.9% stake, to cooperate on CBD products

AMC Entertainment

The bullish sentiment continued on Wall Street.

Why a Pot Stock and a Pandemic-Crushed Business Are Leading the Stock Market Higher Thursday

The cannabis grower and the tobacco giant will jointly develop new CBD-based consumer products.

British American Tobacco Takes 20% Stake in Organigram

Investors think a strategic investment from big tobacco improves the company's prospects.

Why Organigram Holdings Stock Spiked 30% Today

Shares of Organigram soared as much as 47% on Thursday after British American Tobacco invested $176 million into the Canada-based cannabis producer for a 19.9% equity stake in the firm. The strategic investment will accelerate Organigram's research and development and product pipeline development, with both companies entering into a product collaboration agreement. The two firms' first collaborative product venture will be in the CBD space.

Organigram soars 47% after British American Tobacco invests $177 million in the cannabis producer

OrganiGram is on the move today thanks to a new deal with British American Tobacco. Here's what to know about OGI stock now.

OGI Stock: Why Pot Play OrganiGram Is Soaring Today

The stock price of OrganiGram Holdings Inc. (Nasdaq: OGI) has increased by over 40% pre-market. This is why it happened.

OGI Stock Price Increases Over 40% Pre-Market: Why It Happened

British American Tobacco said on Thursday it will buy a nearly 20% stake in Canada-based cannabis producer Organigram for about 126 million pounds ($175.81 million) as it diversifies beyond its main tobacco business.

BAT to pick up stake in Canada-based pot producer Organigram

Organigram Holdings Inc's U.S.-listed shares soared 47% in premarket trade Thursday, after the Canadian cannabis company said it has received a C$221 million ($176.6 million) investment from a unit of British American Tobacco PLC . The tobacco company has subscribed for about 58.3 million shares of Organigram, equal to a 19.9% stake at a price per share of C$3.792, based on a five-day volume weighted average price on the TSX ending March 9, 2021.

British American Tobacco invests $176.6 million in Organigram and will develop CBD products; Organigram up 47% premarket

MONCTON, New Brunswick--(BUSINESS WIRE)---- $OGI--Organigram Holdings Inc. (“OGI”, TSX: OGI and NASDAQ: OGI) is pleased to announce a C$221 million strategic investment from a wholly-owned subsidiary of BAT (LSE:BATS and NYSE:BTI). The BAT subsidiary has subscribed for approximately 58.3 million common shares of OGI, which represents a 19.9% equity interest1 on a post-transaction basis for total proceeds of approximately C$221 million (“Investment Proceeds”) at a price per share of C$3.792, based on a f

Organigram and BAT Form Product Development Collaboration – Includes Strategic Investment from BAT for 19.9% Equity Interest

Off and on the price chart, OGI stock is showing it could be around a lot longer and in better position than today's meme-driven crowd. The post Organigram Holdings Stock Is More Theme Than Meme appeared first on InvestorPlace.

Organigram Holdings Stock Is More Theme Than Meme

OGI stock is nearing its 2020 levels. However, at $3 the stock is a more realistic bet than when it was trading at $6.

Organigram Is Coming Back to Earth, And That's Good for Speculative Investors

Canopy Growth

Stocks of the Canadian pot growers are reversing a recent downtrend today.

Why Canopy Growth, Organigram Holdings, and HEXO Shares Jumped Tuesday

Yamana Gold

These tiny stocks could deliver in a big way for investors.

3 Penny Stocks That Can Double Your $1,400 Stimulus Check

There's a credible chance that it will boom later this year.

Should You Buy OrganiGram in March?

Cronos Group

SNDL Inc.

Tilray Brands

Marijuana stocks have been up and down for several years and still seek firm footing. Right now, these seven aren't worth your money.

7 Marijuana Stocks That Look Way Too Expensive Here

Yet, given its less frothy valuation, and its potential for outsized gains if its own results (or legalization odds) improve, consider OGI stock a worthwhile gamble in this high-risk sector. The post Meme Status Aside, Organigram Stock Is Well Worth the Gamble appeared first on InvestorPlace.

Meme Status Aside, Organigram Stock Is Well Worth the Gamble

OGI stock is one of the most volatile cannabis stocks. Yet, if you can handle the roller coaster ride, a small position might be justified.

As OrganiGram Stock Gets Cheaper, Investors Can Reduce Their Cost Basis

Curaleaf Holdings, Inc.

GW Pharmaceuticals

Jazz Pharmaceuticals

MedMen Enterprises Inc.

Each of these cannabis stocks blazed higher by between 20% and 208% last month.

The 10 Best Marijuana Stocks in February

OGI stock has risen meteorically. No one should buy the shares now, as OrganiGram has obvious operational issues.

Why Investors Should Avoid OrganiGram

MONCTON, New Brunswick--(BUSINESS WIRE)---- $OGI--As part of its consumer-first product innovation strategy, Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading producer of cannabis, is pleased to announce the launch of two new additions to the Company's recreational cannabis product portfolio: SHRED Tropic Thunder Jar of Joints and Trailblazer SNAX Milk Chocolate Bars. “At Organigram, seeking out and acting upon consumer fe

News for OrganiGram Holdings Inc. Stock (OGI)